Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Peripheral Perfusion Index trajectory to predict 28-day mortality in sepsis patients in the ICU

Official title: Peripheral Perfusion Index Trajectory as a Predictor of 28-Day Mortality and Its Incremental Value Over SOFA and Lactate in Patients With Sepsis and Septic Shock: A Prospective Observational Cohort Study

Run by Trakya University · NCT07740304 · Data updated 2026-11-12

This study tests whether changes in a finger-based perfusion index over the first 24 hours in the ICU can predict 28-day death among adults with sepsis or septic shock.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment400 (estimated)
SponsorTrakya University
Academic / other
Locations2 sites (Edirne, Merkez and 1 other locations)
StatusRecruiting
StartedJuly 6, 2026
Main results expectedAugust 7, 2027
Study endsOctober 7, 2027
Registry record updatedOctober 14, 2026
Trial IDNCT07740304 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with sepsis or septic shock admitted to participating ICUs within 6 hours of admission.

Probably not a fit

Patients with conditions that preclude reliable PI measurement or those outside the 6-hour enrollment window may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study will track the peripheral perfusion index, derived from standard pulse oximetry, over the first 24 hours of ICU stay in adults with sepsis or septic shock. It aims to determine if PI trajectory adds predictive value for 28-day mortality beyond existing severity scores like SOFA. Additional bedside measures such as capillary refill time and skin mottling score will be recorded. The study does not introduce a treatment, but seeks to improve risk stratification by capturing microcirculatory perfusion dynamics. Enrollment is within 6 hours of ICU admission, and participation requires informed consent.

Why it matters

Potential benefit: If PI trajectory proves predictive, clinicians may improve early risk stratification and potentially tailor monitoring intensity for high-risk patients.

How similar studies have gone: Previous studies suggest a link between microcirculatory perfusion and outcomes, but dynamic PI trajectory as a predictor is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older
* Diagnosis of sepsis or septic shock according to Sepsis-3 criteria (suspected or confirmed infection with an acute increase in SOFA score of 2 points or more)
* Enrollment possible within the first 6 hours of intensive care unit admission
* Written informed consent obtained from the patient or, when the patient lacks decision-making capacity, from a legal representative, in accordance with the approved consent procedure

Exclusion Criteria:

* Conditions precluding valid peripheral perfusion measurement at both measurement sites, including severe peripheral arterial disease, limb ischemia or amputation, extensive edema or burns, or local trauma at the measurement site
* Intensive care unit stay of 24 hours or longer at another facility prior to admission
* Decision to withdraw or limit life-sustaining treatment planned within the first 24 hours
* Pregnancy
* Severe Raynaud phenomenon or vasospastic disease of the extremities
* Persistent tremor or agitation precluding standardized measurement
* Concurrent enrollment in an interventional study

Where it's running

  • Trakya University Faculty of Medicine, Department of Internal Medicine, Division of Intensive Care Medicine
    Edirne, Merkez, Turkey (Türkiye)
    Recruiting
  • Uzunköprü State Hospital, Intensive Care Unit
    Edirne, Uzunköprü, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Faruk Yildiz, Md — Trakya University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.